LivaNova PLC (NASDAQ:LIVN) Receives $59.29 Consensus Target Price from Brokerages

LivaNova PLC (NASDAQ:LIVN - Get Free Report) has been given a consensus rating of "Buy" by the eight brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $59.29.

Several analysts have recently weighed in on LIVN shares. Mizuho decreased their target price on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Robert W. Baird upped their target price on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target for the company in a research note on Tuesday, May 20th. The Goldman Sachs Group dropped their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Finally, Wall Street Zen downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th.

LivaNova Trading Down 2.8%

LIVN traded down $1.23 on Tuesday, hitting $42.79. The company had a trading volume of 513,422 shares, compared to its average volume of 651,905. The business's fifty day simple moving average is $38.86 and its 200 day simple moving average is $44.48. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova has a 12-month low of $32.48 and a 12-month high of $61.94. The company has a market cap of $2.33 billion, a PE ratio of 101.88 and a beta of 0.84.

Hedge Funds Weigh In On LivaNova

Several institutional investors have recently bought and sold shares of LIVN. KBC Group NV boosted its position in LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company's stock valued at $4,628,000 after acquiring an additional 56,580 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of LivaNova by 29.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock worth $292,000 after purchasing an additional 1,424 shares during the last quarter. Rhumbline Advisers boosted its position in LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after purchasing an additional 899 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in LivaNova during the fourth quarter valued at about $2,772,000. Finally, Envestnet Asset Management Inc. grew its stake in LivaNova by 15.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock valued at $2,034,000 after purchasing an additional 5,850 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.